This non-randomized, open-label, two-arm study was designed to demonstrate non-inferiority of efficacy with respect to virologic response of PEGASYS plus Copegus in treatment-naive Latino patients with chronic hepatitis C, genotype 1, as compared to treatment naive non-Latino White patients with chronic hepatitis C genotype 1, both over 48 weeks of treatment, at 52 treatment centers in the US.